ATOS•benzinga•
Atossa Therapeutics Reports Full Results From Phase 2 EOP Sub‑Study Within I‑SPY 2 Trial Evaluating Low‑Dose Oral (Z)‑Endoxifen As Neoadjuvant Treatment In 20 Women With Stage II/III ER+, HER2‑Negative Breast Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 14, 2025 by benzinga